Grail
Grey’s Anatomy Star Kate Walsh Partners with GRAIL for Multi-Cancer Early Detection Awareness Campaign
Kate Walsh, GRAIL, multi-cancer early detection (MCED), Generation Possible, cancer screening, blood test
EU High Court Rules in Favor of Illumina in Grail Acquisition Appeal
Illumina, Grail, European Court of Justice, Acquisition, Antitrust Litigation, Liquid Biopsy
Grail Lays Off About 350 Employees, Puts Brakes on New Hires
Grail, layoffs, restructuring, biotech, cancer detection, Galleri test, Illumina, workforce reduction, cost-cutting measures
Illumina’s Board Approves Spin-Off of Grail, a Cancer Diagnostics Firm
Illumina, Grail, spin-off, cancer diagnostics, DNA sequencing
CMS to Increase Reimbursement for New Sickle Cell Gene Therapies through Outcomes-Based Agreements
CMS (Centers for Medicare & Medicaid Services), Sickle Cell Gene Therapies, Increased Reimbursement, Outcomes-Based Agreements (OBAs), Cell and Gene Therapy (CGT) Access Model, Medicaid Access, Casgevy, Lyfgenia, Fertility Preservation Services, Equitable Access, Administrative Burden Reduction
Pfizer Discontinues Phase III Trial for Sickle Cell Treatment Amid Challenges in Patient Recruitment
Pfizer, Sickle Cell Disease, Phase III Study, Inclacumab, Poor Accrual, Recruitment Challenges, THRIVE Program, ClinicalTrials.gov, Gene Therapies
Orchard Therapeutics Sets $4.25 Million Price Tag for Leukodystrophy Gene Therapy
Orchard Therapeutics, Leukodystropy, Gene Therapy, Lenmeldy, $4.25 million US price tag
4DMT’s Gene Therapy Reduces Eylea Injections, Advancing Plans for Phase 3 Trial in Wet AMD
Glycogen storage disease type II, 4DMT, gene therapy, Trial Phase
Shanghai startup’s gene therapy restores hearing in five deaf children, running ahead of Lilly and Regeneron trials
Child, Hearing, Hearing Impaired Persons, gene therapy
Lillys Investigational Gene Therapy Restores Hearing in First Treated Patient
Hearing, Treating, gene therapy, AK-OTOF